Effect of Continuous Intake of Ergothioneine-containing Supplements on Skin Condition
Launched by SHANGHAI EGT SYNBIO GROUP CO., LTD. · Mar 13, 2025
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
Ergothioneine (EGT), a naturally occurring amino acid-like antioxidant, was first discovered in Clavieps purpurea in 1909. It is widely found in mushrooms, legumes, and certain animal tissues. Studies have shown that ergothioneine protects skin cells by scavenging free radicals and reducing oxidative stress, thereby delaying skin aging. Additionally, it can inhibit melanin production, improve uneven skin tone, enhance the skin barrier function, and boost skin elasticity and radiance. In recent years, with growing attention to nutricosmetics, ergothioneine has gained significant interest for...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • ① Healthy women aged 35 to 59 years old.
- • ② Individuals who feel that their skin condition is deteriorating (loss of radiance, dullness, pigmentation spots, etc.).
- Exclusion Criteria:
- • Individuals with a history of food allergies.
- • Pregnant or breastfeeding individuals.
- • Individuals with inflammation or wounds on their face.
- • Individuals taking medication that could affect the trial. ⑤ Individuals consuming health supplements that could affect the trial.
- • ⑥ Individuals currently undergoing medical treatment or receiving prescriptions from a doctor.
- • ⑦ Individuals undergoing hormone therapy.
- • ⑧ Individuals with eyelash extensions, permanent eyeliner, or other forms of cosmetic tattooing around the eyes.
- • ⑨ Individuals who have participated in human clinical trials within the last month or plan to do so during the trial period.
- • ⑩ Individuals deemed unsuitable by the principal investigator of the trial.
About Shanghai Egt Synbio Group Co., Ltd.
Shanghai EGT Synbio Group Co., Ltd. is a leading biotechnology company specializing in the development and commercialization of innovative synthetic biology solutions. With a strong focus on advancing healthcare and agricultural applications, the company leverages cutting-edge research and technology to create novel therapies and products. Committed to excellence in clinical trials, Shanghai EGT Synbio Group aims to enhance patient outcomes and contribute to the global biopharmaceutical landscape through rigorous scientific methodologies and a collaborative approach to research and development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, Shinjukuku, Japan
Patients applied
Trial Officials
Kaneko Takeshi
Principal Investigator
Japan Clinical Trial Association
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported